We are open if you require Sexual health/Contraception care, please continue to call our central booking line on 01904 721111 and press option 1.

Central booking line is open from - Monday – Thursday 8:15am – 5pm & Friday 8:15am – 4pm. Saturday 9am-12pm.

You will be assessed by our team and one of our nurses will call you to discuss the best way to get you the care you require.

If you require a STI screen only and you have no symptoms you may prefer to order a testing kit online from the website

https://www.yorsexualhealth.org.uk/sexually-transmitted-infections-stis/postal-testing/

 

 

Close

For information on coronavirus (COVID-19), please visit https://www.yorsexualhealth.org.uk/coronavirus-corvid-19-information/

Professionals

I would like to see current sexual health news

April 2020 - Coronavirus (Covid-19) guidance for professionals

The ADPH UK - COVID-19 guidance/ recommendations on the Prioritisation of Sexual & Reproductive Health Services has just been published, as four downloadable PDF docs.

FSRH advice for women seeking contraception, abortion and SRH advice during the COVID-19 pandemic

Please note current contraceptive advice includes:

Supported extended use of nexplanon to 4 years, mirena/levosert to 6 years and T-safe 380 to 12 years. Prescribing of combined hormonal contraception can be extended by up to 12 months if a woman has had a BP and BMI reading which was satisfactory within the last 12 months.

FPA/Sexwise unplanned pregnancy/abortion and Covid-19

BASHH support for local responses to COVID-19 and contingency planning

NHS Cervical Screening Programme Guidance for Sample Taking during Coronavirus pandemic

Sexwise Information for Professionals

Safe sex reminder as antibiotic resistant gonorrhoea investigations continue

Public Health England (PHE) is issuing a reminder to the public to practise safe sex by using a condom with new or casual partners.

The call comes as an increase in antibiotic resistant cases of gonorrhoea continues, a further sign of the very real threat of antibiotic resistance to our ability to treat infections.

Finding this sort of extensively drug resistant gonorrhoea in the UK serves as an important reminder of the need to practice safer sex. This includes using condoms consistently and correctly with all new and casual sexual partners. Anyone with symptoms of a sexually transmitted infection (STI) or who is concerned they may have an STI should seek advice from their sexual health clinic.

For more information visit https://www.gov.uk/government/news/two-cases-of-resistant-gonorrhoea-diagnosed-in-the-uk

At the present time, the advice to frontline clinicians remains unchanged - as before we would still be advising all cases of suspected/confirmed gonorrhoea to be referred to local sexual health services for appropriate management, encouraging regular STI testing and protected sex with condoms.

Chlamydia treatment guidelines changed in September 2018

BASHH:

Chlamydia treatment guidelines changed in September 2018:

First line treatment is Doxycycline 100mg bd for seven days (contraindicated in pregnancy) and second line treatment is  Azithromycin 1g orally as a single dose, followed by 500mg once daily for two days

Publication of updated guideline for the management of infection with Neisseria gonorrhoeae (2019) The updated guideline for the management of infection with Neisseria gonorrhoeae is available at https://www.bashh.org/guidelines Changes since the 2011 guideline include: •    First line empirical treatment is now monotherapy with ceftriaxone 1g  •    If antimicrobial susceptibility test results from all sites of infection are available prior to treatment and the isolate is sensitive to ciprofloxacin, then this should be used for treatment in preference to ceftriaxone •    Recommendations for extra-genital testing in those with suspected or confirmed antimicrobial resistance  •    Epidemiological treatment is recommended only for those presenting within 14 days of exposure. For those presenting after 14 days of exposure we recommend treatment based on the results of testing.

The recent changes from the Neisseria gonorrhoeae, chlamydia treatment guidelines and the publication of BASHH Mycoplasma genitalium guidelines have impacted upon the first line treatment for Pelvic inflammatory disease, non-gonococcal urethritis. Please see BASHH website for the guidelines: https://www.bashh.org/guidelines

FRSH:

Combined Hormonal Contraception

The FSRH CHC Clinical Guideline is now available on the FSRH website  https://www.fsrh.org/news/fsrh-publishes-clinical-guideline-on-combined-hormonal/

What is new in this guideline?

Latest news View all news

YorSexualHealth